BioNTech Analyst Price Targets - Benzinga

BioNTech SE

BNTXNASDAQ

Trade with Public

Trade with Public

$87.53

-0.64-0.73%

最終更新: Nov 3, 6:24 AM

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

© 2026 Benzinga | All Rights Reserved

BioNTech Analyst Price Targets - Benzinga

BioNTech Analyst Price Targets

Wall Street analyst price targets and consensus rating for BioNTech (BNTX).

Price Target Range — 12 Quarters

Analyst Consensus — 17 Analysts

13Buy

4Hold

Consensus RatingBuy# Analysts17Avg. Consensus PT$131Upside to Avg. PT+49.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 14, 2026	Canaccord Genuity	John Newman	PT Cut	Buy	$136→$132
Oct 7, 2026	Morgan Stanley	Terence Flynn	PT Cut	Overweight	$115→$114
Sep 8, 2026	BMO Capital	Evan Seigerman	Downgrade	Outperform→Market Perform	$128→$105
Aug 31, 2026	Canaccord Genuity	John Newman	PT Cut	Buy	$142→$136
Aug 5, 2026	Citigroup	Geoff Meacham	PT Cut	Buy	$130→$125
Aug 5, 2026	Evercore ISI Group	Cory Kasimov	PT Cut	Outperform	$135→$130
Jul 8, 2026	Morgan Stanley	Terence Flynn	PT Cut	Overweight	$126→$119
May 27, 2026	UBS	David Dai	Upgrade	Neutral→Buy	$117→$135
May 22, 2026	Bernstein	Jeffrey Walch	Initiate	Market Perform	$96
May 6, 2026	Canaccord Genuity	John Newman	PT Cut	Buy	$171→$158
May 6, 2026	Wells Fargo	Mohit Bansal	PT Cut	Overweight	$150→$140
Apr 27, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$130
Apr 10, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$125→$126
Mar 31, 2026	HC Wainwright & Co.	Robert Burns	PT Cut	Buy	$140→$130
Mar 11, 2026	Morgan Stanley	Terence Flynn	PT Cut	Overweight	$134→$125
Mar 11, 2026	Canaccord Genuity	John Newman	Maintained	Buy	$171
Mar 11, 2026	Citigroup	Geoff Meacham	PT Cut	Buy	$145→$130
Mar 11, 2026	TD Cowen	Yaron Werber	PT Cut	Hold	$116→$94
Mar 11, 2026	BMO Capital	Etzer Darout	PT Cut	Outperform	$143→$128
Mar 10, 2026	Jefferies	Akash Tewari	PT Cut	Buy	$151→$138

Analyst Ratings News

PRO
Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $132

Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $136 to $132.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $114

Morgan Stanley analyst Terence Flynn maintains BioNTech (NASDAQ:BNTX) with a Overweight and lowers the price target from $115 to $114.

Benzinga Newsdesk

This Best Buy Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday

Analysts downgraded BioNTech, Gulfport Energy, Amgen and Best Buy; price targets fell for BioNTech and Gulfport.

Avi Kapoor

Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday

Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings largely remain positive.

Avi Kapoor

PRO
BMO Capital Downgrades BioNTech to Market Perform, Lowers Price Target to $105

BMO Capital analyst Evan Seigerman downgrades BioNTech (NASDAQ:BNTX) from Outperform to Market Perform and lowers the price target from $128 to $105.

Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $136

Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $142 to $136.

Benzinga Newsdesk